How to Get the $50 GLP-1 Copay: A Step-by-Step Medicare GLP-1 Bridge Guide

For the first time, Medicare is helping pay for GLP-1 medications prescribed solely for weight loss — not just for diabetes or heart disease. Under the Medicare GLP-1 Bridge, a federal demonstration announced by CMS and running from July 1, 2026 through December 31, 2027, eligible Part D beneficiaries pay a flat $50 per month for covered GLP-1s such as Wegovy and Zepbound. KFF estimates roughly 3.8 million Medicare beneficiaries meet the program's clinical bar.

The most common misunderstanding we hear is that you need to "sign up" somewhere. You don't. The Bridge is built into Part D automatically — the gateway is a prior authorization submitted by your doctor. This guide walks through each step, what can go wrong, and what to do if you are turned down.

The Bridge operates through Medicare Part D. You qualify for consideration if you have either a standalone Part D prescription drug plan alongside Original Medicare, or a Medicare Advantage plan that includes drug coverage (MA-PD). If you have Medicare but no drug coverage at all, you would need to join a Part D plan during a valid enrollment period first.

One helpful design choice: CMS made participation automatic on the plan side. Part D sponsors do not have to opt in, so you do not need to worry about whether your particular insurer "participates." If you are an eligible Part D beneficiary, the program applies to you.

Eligibility is defined by CMS in three clinical categories. You must fit through one of these doors:

This is the step where access is won or lost. Your prescriber submits a prior authorization (PA) request to your Part D plan that attests two things:

1. You meet one of the three clinical categories above (with the supporting BMI measurement and any qualifying diagnosis documented in your chart); and
2. The GLP-1 is being prescribed to reduce excess body weight and for ongoing maintenance of weight reduction — that exact purpose, not a diabetes or off-label indication.

Before your appointment, it helps to bring: a current medication list, records of any qualifying conditions (for Doors 2 and 3), and recent lab work if you have it. If your qualifying condition was diagnosed by a different doctor — say, a cardiologist documented your heart attack — make sure those records are in the file your prescriber can reference.

Standard Part D coverage determinations come back within 72 hours, or 24 hours for expedited requests where a delay could seriously harm your health. If you have never been through a PA before, our prior authorization guide explains the process in plain language.

Once the PA is approved, your pharmacy can process the prescription at a flat $50 per 30-day supply. A few mechanics worth knowing, because they differ from normal Part D billing:

• $50 at every dose level. The copay does not increase as your doctor titrates you up to a higher dose.
• No deductible hurdle. You do not have to meet your Part D deductible before the $50 price applies.
• It runs outside the normal benefit phases. The Bridge operates separately from standard Part D. That has one important downside: your $50 payments do not count toward your deductible or the $2,100 annual out-of-pocket cap. We break down what that means for your yearly budget in our Part D cap and GLP-1s guide.
• No stacking coupons. Manufacturer copay cards and coupons cannot be combined with the Bridge price.

The covered set is narrower than "any GLP-1." Program materials list:

• Wegovy (semaglutide, Novo Nordisk) — injection and the oral tablet formulation
• Zepbound (tirzepatide, Eli Lilly) — specifically the KwikPen formulation
• Foundayo (Eli Lilly) — the once-daily oral GLP-1 pill
• Ozempic (semaglutide) — referenced in CMS program materials alongside the others

Behind the scenes, the federal government negotiated a "most-favored-nation" net price of about $245 per month with both manufacturers — that is what makes the $50 beneficiary copay possible. See our covered drugs page for the full comparison table.

A denial is not the end of the road — it is usually a documentation problem. The most common causes we see: the BMI was not recorded at a recent visit, the qualifying comorbidity is not coded in the chart the prescriber submitted, or the request did not attest to weight reduction as the purpose. All three are fixable with a corrected resubmission.

You also have formal appeal rights under Part D, with strict decision deadlines that work in your favor. Our step-by-step guide, What to Do When Your GLP-1 Prior Authorization Is Denied, covers the redetermination process, sample language, and when to escalate.